TRAIL对HeLa生物活性及其作用机理的初步研究
摘要
肿瘤坏死因子相关凋亡诱导配体(TNF-related apoptosis-inducing ligand，TRAIL)是继TNF、FasL之后发现的肿瘤坏死因子超家族新成员，具有选择性地诱导癌化或转化的细胞发生凋亡，对正常细胞及人体组织安全无毒，同时，TRAIL可以不依赖p53。因此，TRAIL受到了国内外学者的广泛重视，有望成为新的抗肿瘤药物。
然而，目前，TRAIL对宫颈癌的作用机理并不十分清楚，仅停留于对某一种或某几种蛋白质的功能研究，难以在特定的时间和特定的空间整体地、系统地、透彻地阐释TRAIL的作用机制。本研究以HPV18阳性的宫颈癌细胞系HeLa为模型，通过原核表达系统表达的TRAIL蛋白，开展了TRAIL蛋白的生物学活性，作用靶位及作用机理的初步研究，总的结果是为TRAIL的作用靶点及作用机理提供新的理论依据。
我们的研究分四个部分进行。
第一部分 人可溶性TRAIL cDNA的克隆及原核表达系统的构建
利用基因工程技术克隆人可溶性TRAIL胞外区114～281片段的cDNA及构建其原核表达载体pET28c(+)-sTRAIL。将pET28c(+)-sTRAIL转化大肠杆菌BL21(DE3)，经氨苄西林筛选，建立原核表达系统pET28c(+)-sTRAIL/BL21(DE3)，该系统经用1.0mmol／LIPTG诱导4h，得获了TRAIL融合蛋白，纯化并鉴定，表明，其分子量约为19.8kD。
第二部分 TRAIL对HeLa生物活性的研究
用TRAIL蛋白干预HeLa，经过MTT法检测细胞存活分数；AO／EB
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is one of the membrane-binding cytokines that belongs to the family of tumor necrosis factor (TNF). TRAIL has been shown to be a potent apoptosis inducer in a wide variety of cancer cells in vitro and to limit tumor growth efficiently in vivo without damaging normal tissues dependent on or not p53. These functions of TRAIL suggest that it might be a potential therapeutic agent to treat human cancers.
However, up to date, the role of TRAIL in cervical cancer is not very clear except functional studies of certain proteins. It's difficult to thoroughly explain the role of TRAIL, in a particular time and specific space. In this paper, first , we have cloned cDNA of human TRAIL, and obtained TRAIL protein in the prokaryotic expression system . Next, with HPV18-positive cervical cancer cell lines HeLa as model, we have studied the biological activity of TRAIL, target proteins by Comparative Proteomics. The overall results laid a solid theoretical foundation for further research on the role and mechanisms of TRAIL .
Our study is composed of four contents.
Part I Cloning of human soluable TRAIL and expression in prokaryotic expression system .
By means of genetic engineering technology, TRAIL codons 114～118 gene were amplified by RT-PCR, transformed into coli BL21 (DE3), and
然而，目前，TRAIL对宫颈癌的作用机理并不十分清楚，仅停留于对某一种或某几种蛋白质的功能研究，难以在特定的时间和特定的空间整体地、系统地、透彻地阐释TRAIL的作用机制。本研究以HPV18阳性的宫颈癌细胞系HeLa为模型，通过原核表达系统表达的TRAIL蛋白，开展了TRAIL蛋白的生物学活性，作用靶位及作用机理的初步研究，总的结果是为TRAIL的作用靶点及作用机理提供新的理论依据。
我们的研究分四个部分进行。
第一部分 人可溶性TRAIL cDNA的克隆及原核表达系统的构建
利用基因工程技术克隆人可溶性TRAIL胞外区114～281片段的cDNA及构建其原核表达载体pET28c(+)-sTRAIL。将pET28c(+)-sTRAIL转化大肠杆菌BL21(DE3)，经氨苄西林筛选，建立原核表达系统pET28c(+)-sTRAIL/BL21(DE3)，该系统经用1.0mmol／LIPTG诱导4h，得获了TRAIL融合蛋白，纯化并鉴定，表明，其分子量约为19.8kD。
第二部分 TRAIL对HeLa生物活性的研究
用TRAIL蛋白干预HeLa，经过MTT法检测细胞存活分数；AO／EB
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is one of the membrane-binding cytokines that belongs to the family of tumor necrosis factor (TNF). TRAIL has been shown to be a potent apoptosis inducer in a wide variety of cancer cells in vitro and to limit tumor growth efficiently in vivo without damaging normal tissues dependent on or not p53. These functions of TRAIL suggest that it might be a potential therapeutic agent to treat human cancers.
However, up to date, the role of TRAIL in cervical cancer is not very clear except functional studies of certain proteins. It's difficult to thoroughly explain the role of TRAIL, in a particular time and specific space. In this paper, first , we have cloned cDNA of human TRAIL, and obtained TRAIL protein in the prokaryotic expression system . Next, with HPV18-positive cervical cancer cell lines HeLa as model, we have studied the biological activity of TRAIL, target proteins by Comparative Proteomics. The overall results laid a solid theoretical foundation for further research on the role and mechanisms of TRAIL .
Our study is composed of four contents.
Part I Cloning of human soluable TRAIL and expression in prokaryotic expression system .
By means of genetic engineering technology, TRAIL codons 114～118 gene were amplified by RT-PCR, transformed into coli BL21 (DE3), and
引文
[1]. Wiley SR, Seheoley K, Cmolak P J, et al.1 dentification and charac- terization of a new member of the TNF family that induce apoptosis[J]. Immunity, 1995, (6): 673-682
[2]. Liabakk, N. B, Sundan, et al.characterization and use of monoclonal antibodies against TRAIL: measurementof TRAIL by ELISA. J. Immunol[J]. Methods, 2002, (259): 119-128
[3]．史治宙，宋朝君，黄威权，等．肿瘤坏死因子相关凋亡诱导配体在外周血单个核细胞中的表达[J]．解剖学杂志，2005，28(1)：29-30
[4]．陈江，陈晓春，曾甫清，等．TRAIL受体在前列腺癌中的表达[J]．现代泌尿外科杂志，2004，9(1)：3-5
[5]．李春梅，彭芝兰，杨开选，等．TRAIL及其受体和Fas—L在卵巢癌组织中的表达[J]．四川大学学报：医学版，2005，36(3)：341-343
[6]．阎庆辉，刘津，张国建，等．蔡建辉肿瘤相关凋亡诱导配体、Survivin、Caspase-3和NF-κB在大肠癌中的表达[J]．中华实验外科杂志，2005，22(10)：1197-1197
[7]．宋朝君，刘雪松，陈丽华，等．TRAIL及其受体在正常心脏组织的免疫组织化学定位[J]．心脏杂志，2003，15(6)：490-492
[8]．僧靖静，张云汉，高冬玲．TRAIL、Survivin mRNA表达与胃癌凋亡发生的相关关系[J]．河南大学学报：医学版，2005，24(1)：25-28
[9]．任秀花，张华，吴红霞，等．食管癌发生发展过程中TRAIL和Survivin蛋白的表达研究[J]．河南肿瘤学杂志，2005，18(5)：305-306
[10]. Yao GH, Hou YY . Recent advances for research on anti-tumor effects of TNF-related apoptosis-inducing ligand[J]. Wei Sheng Yan Jiu, 2006 , 35(1): 115-117
[11]. Pathil A, Armeanu S, Venturelli S, et al. HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL[J]. Hepatology, 2006, 43(3): 425-434
[12]. Vitale M, Gobbi G, Mirandola P, et al. TNF-RELATED APOPTOSIS-inducing ligand (TRAIL) and erythropoiesis: a role for PKC(epsilon)[J]. Eur J Histochem, 2006, 50(1): 15-18
[13]. Pathil A, Armeanu S, Venturelli S, et al. HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity toTRAIL[J]. Hepatology, 2006, 43(3): 425-434
[14]. Chang JY, Zhang X, Komaki R, et al. Tumor-specific apoptotic gene targeting overcomes radiation resistance in esophageal adenocarcinoma[J]. Int J Radiat Oncol Biol Phys, 2006, 64(5): 1482-1494
[15]. Haines JF, TRAIL IA, Nuttall D, et al. The results of arthroplasty in osteoarthritis of the shoulder[J]. J Bone Joint Surg Br, 2006, 88(4): 496-501
[16]．梁晓红，孙汶生，高立芬，等．乙型肝炎病毒X蛋白调节TRAIL诱导的肝细胞凋亡[J]．中国科学：C辑，2005，35(1)：59-67
[17]．杜秀敏，游木荣，齐法莲，等．TRAIL及NF—kB在骨肉瘤中的表达、及其意义标记[J]．免疫分析与临床，2005，12(2)：65-66，69
[18]．何超，胡文献，胡晓彤，等．γ-干扰素加强TRAIL抑制人大肠癌细胞株作用的研究[J]．中国病理生理杂志，2006，22(2)：365-367
[19]．张智峰，牛光明，宋来君，等．肿瘤坏死因子相关凋亡诱导配体诱导人脑胶质瘤细胞凋亡作用的研究[J]．中国基层医药，2005，12(10)：1311-1313
[20]．范清林，魏伟，邹文艺，等．人TRAIL基因的克隆、表达、纯化及对人A549细胞的抗肿瘤活性作用[J]．中国药理学通报，2006，22(2)：228-233
[21]．周莉，闫明霞，姚明，等．转染TRAIL的内皮祖细胞对人卵巢癌裸鼠皮下移植瘤的抑制作用[J]．癌症，2005，24(11)：1312-1316
[22]．刘培淑，白琴，侯萍，等．TRAIL对3AO裸鼠移植瘤治疗作用的实验研究[J]．现代妇产科进展，2004，13(2)：114-116，119
[23]．王正兵，贾筱琴，陈兵，等．TRAIL真核表达．质粒的构建及抑制肝癌生长的实验研究[J]．中国普外基础与临床杂志，2005，12(3)：261-264
[24]. Kaliberov SA , Kaliberova LN, Stockard CR, et al . Buchsbaum DJ. Adenovirus-mediated FLT1-targeted proapoptotic gene therapy of human prostate cancer[J]. Mol Yher, 2004, 10(6): 1059-1070
[25]. Reddy RM, Tsai WS, Ziauddin MF, et al. Cisplatin enhances apoptosis induced by a tumor-selective adenovirus expressing rumor necrosis factor-related apoptosis-inducing ligand[J]. J Thorac Cardiovasc Surg, 2004, 128(6): 883-891
[26]. Jacob D, Davis J, Schumacher G, et al. Adenoviral vector expressing the TRAIL gene driven by the hTERT promoter[J]. Z Gastroenterol, 2004, 42(12): 1363-1370
[27]．李宁，范学工，人TRAIL分子的克隆、表达．及鉴定[J]．中国现代医学杂志，2004，14(3)：82-85
[28]．路丽明，李宁丽，沈佰华，等．TRAIL分子胞外区基因工程蛋白的制备与鉴定[J]．中国实验诊断学，2003，7(6)：477-479
[29]. Li HM, Song TB, Yu YC, et al. Construction of TRAIL gene eukaryotic expression vector modulated by hTERT gene core promoter and its effect on apoptosis of ovarian cancer cells[J]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, 2006, 22(2): 243-246
[30]．王梁华，焦炳华．人TRAIL在毕氏酵母表达系统中的表达[J]．细胞与分子免疫学杂志，2000，16(5)：420-424
[1]．李小安，房殿春，司佩任，等．TRAIL诱导肝癌细胞系SMMC—7721的凋亡作用[J]．世界华人消化杂志，2003，11，9：1369-1371
[2]．何松青，陈彦，陈孝平．TRAIL的抗肝细胞癌作用研究[J]．中华肝胆外科杂志，2003，9，11：670-673
[3]．杨柳芹，房殿春．α-生育酚对TRAIL诱导胃癌细胞凋亡的影响及机制[J]．解放军医学杂志，2005，30，9：779-781
[4]. Ma H, Liu Y, Liu S, et al. Oral adeno-associated virus- TRAIL gene therapy suppresses human hepatocellular carcinoma growth in mice[J]. Hepatology, 2005, 42(6): 1355-1363
[5]. Kaliberov SA, Kaliberova LN, Stockard CR, et al. Adenovirus-mediated FLT1-targeted proapoptotic gene therapy of human prostate cancer[J], 2004, 10(6): 1059-1070
[6]. Reddy RM, Tsai WS, Ziauddin MF, et al. Cisplatin enhances apoptosis induced by a tumor-selective adenovirus expressing tumor necrosis factor-related apoptosis-inducing ligand[J]. J Thorac Cardiovasc Surg, 2004, 128(6): 883-891
[7]. Kazhdan I, Marciniak RA. Death receptor 4 (DR4) efficiently kills breast cancer cells irrespective of their sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)[J]. Cancer Gene Ther, 2004 , 11(10):691-698
[8]. Shankar S, Chen X, Srivastava RK. Effects of sequential treatments with chemotherapeutic drμgs followed by TRAIL on prostate cancer in vitro and in vivo[J]. Prostate, 2005, 1, 62(2): 165-186
[9]. Jacob D, Davis J, Schumacher G, et al. Adenoviral vector expressing the TRAIL gene driven by the hTERT promoter[J]. Z Gastro- enterol, 2004, 42(12): 1363-1370
[10]．朱琳，李慧荣，吴建，等．宫颈癌细胞TRAIL死亡受体和诱骗受体表达的研究[J]．现代妇产科进展，2005，14，4：277-280
[11]. Xiang M, Lin YZ, Zhu SL. MTT colorimetric assay for the biological actibity of hepatic stimulator substance[J]. Xin Xiao Hua Bing Xue Za zhi, 1996, 4: 428-431
[12]. Wang CY, James E, Jim L, et al. Spontaneous apotosis in human colon tumor cell lines and the relation of WT p53 to apoptosis[J]. Chinese Medical Journal, 1996, 109:537-541
[13]. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group[J]. J Natl Cancer Inst, 1995, 87(11): 796-802
[14]. Lombard I, Vincent-Salomon A, Validire P, et al. Human papillomavirus genotype as a major determinant of the course of cervical[J]. J Clin Oncol, 1998, 16(8): 2613-2619
[15]. Liss J, Emerich J, Lukaszuk K, et al. The use of PCR technique in the evaluation of the frequency of HPV infection in vulvar and cervical carcinoma[J] Ginekol Pol, 1998, 69(5): 330-334
[16]. Arakawa K, Ishihara T, Auto M, et al. Action of novel antidiabetic thiazolidinedione, T-174, in animals of non-insulin-dependent diabetesmellitus(NIDDM) and in cultured muscle cells[J]. Br J Pharmacol, 1998, 125:429-436
[17]. Purrello F, Gullo D, Brunetti A, et al. Direct effects of biguanides on glucose utilization invitro[J]. Metabolism, 1987, 36(8): 774-776
[18]．汪承亚，盛瑞兰．细胞凋亡与肿瘤[J]．国外医学生理、病理科学与临床分册，1996，16(4)：291-293
[1]. Pitti RM , Marsters SA, Ruppert S, et al. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine Family[J]. J Biol Chem, 1996, 271(22): 12687—12690
[2]. Choi E, Kim Y, Kim K. The Combination of TRAIL Treatment and Cancer Cell Selective Expression of TRAIL-Death Receptor DR4 Induces Cell Death in TRAIL-Resistant Cancer Cells[J]. Yonsei Med J, 2006, 28;47(1): 55-62.
[3]. Deeb DD, Jiang H, Gao X, et al. Chemosensitizationofhormone-refractory prostate cancer cells by curcumin to TRAIL-induced apoptosis[J]. J Exp Ther Oncol, 2005, 5(2): 81-91
[4]. Chang JY, Zhang X, Komaki R, et al. Tumor-specific apoptotic gene targeting overcomes radiation resistance in esophageal adenocarcinoma[J]. Int J Radiat Oncol Biol Phys, 2006, 64(5): 1482-1494.
[5]. Ortiz-Ferron G, Yait SW, Robledo G, et al. The mitogen-activated protein kinase pathway can inhibit TRAIL-induced apoptosis by prohibiting association of truncated Bid with mitochondria[J]. Cell Death Differ, 2006 , [Epub ahead of print]
[6]. Bollag DM and Edelstein SJ. Protein Methods[M]. Chapter2: protein extraction, Wiley-Liss, NewYork. 1991
[7]. Bradford MM. A rapid and sensitive method for the quantitation of microgram of protein utilizing the principle of protein—dye binding[J]. Anal Biochem, 1976, 72: 248～254.
[8]．钱小红，贺福初．蛋白质组学理论与方法[M]．科学出版社(北京)2003年6月，第一版
[9]. Parkin D M, Bray F, Ferlay J, et al. Estimating the world cancerburden: Globocan [J]. Int J Cancer, 2001, 94:153-156
[10]. Nicolas F S, AndreaT, ElianeDF, et al. Viralload as apredictor of the risk of cervical intraepithelial neoplasia[J]. Int J Cancer, 2003, 103:519-524
[11]. Silva D M , Eiben C'L, Fausch S C, et al. Cervical cancervaccines: emerging concepts and developments[J]. Cell Physiol, 2001, 186(2): 169-182
[12]. Burd E M. Human Papillomavirus and cervical cancer[J], clinMicrobiol Rev, 2o03, 16(1): 1-17
[13]. Horinaka M, Yoshida T, Shiraishi T, et al. The combination of TRAIL and luteolin enhances apoptosis in human cervical cancer HeLa cells[J]. Biochem Biophys Res Commun, 2005, 333(3): 833-838
[14]. Shi RX, Ong CN, Shen HM. Protein kinase C inhibition and x-linked inhibitor of apoptosis protein degradation contribute to the sensitization effect of luteolin on tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in cancer cells[J]. Cancer Res, 2005, 65(17): 7815-7823
[15]. Kim CY, Jeong M, Mushiake H, et al. Cancer gene therapy using a novel secretable trimeric TRAIL[J]. Gene Ther. 2006 , 13(4): 330-338
[16]．夏其昌，曾嵘等．蛋白质化学与蛋白质组学[M]．科学出版社(北京)2004年第一版
[17]. Herr I, Wilhelm D, Meyer E, et al. JNK/SAPK activity contributes to TRAIL-induced apoptosis[J]. Cell Death Differ, 1999, 6(2): 130-135
[18]. Mikami T, Koyama T, Koyama T, et al. C-jun N-terminal kinase activation is required for apoptotic cell death induced by TNF-related apoptosis-inducing ligand plus DNA-damaging agents in sarcoma cell lines[J]. Anticancer Res, 2006, 26(2A): 1153-1160
[19]. Vivo C, Liu W, Broaddus VC, et al. c-Jun N-terminal kinase contributes to apoptotic synergy induced by tumor necrosis factor-related apoptosis-inducing ligand plus DNA damage in chemoresistant, p53 inactive mesothelioma cells[J]. J Biol Chem, 2003, 278(28): 25461-25467
[20]. Kwon D, Cheong JH, Lee JC, et al. Lipopolysaccharides-activated human astroglioma cells induce apoptotic death of T-lymphocytes via c-Jun N-terminal kinases-dependent up-regulation of TRAIL[J]. Neurosci Res, 2006, 54(4): 338-343
[21]. JurewiczA, Matysiak M, Andrzejak S, et al. TRAIL-induced death of human adult oligodendrocytes is mediated by JNK pathway[J]. Glia, 2006, 53(2): 158-166
[22]. Aggarwal BB, Bhardwaj A, Aggarwal RS, et al. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies[J]. Anticancer Res, 2004, 24(5A): 2783-2840.
[23]. Puduvalli VK, Sampath D, Bruner JM, et al. TRAIL-induced apoptosis in gliomas is enhanced by Akt-inhibition and is independent of JNK activation[J]. Apoptosis, 2005, 10(1): 233-243
[24]. Yanase N, Hata K, Shimo K, et al.Requirement of c-Jun NH2-terminal kinase activation in interferon-alpha-induced apoptosis through upregulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in Daudi B lymphoma cells[J].Exp Cell Res, 2005 , 310(1): 10-21
[25]. Oncogene, 199, 14(13): 1563-1570Rousseau S, Dolado I, Beardmore V, et al. CXCL12 and C5a trigger cell migration via a PAKl/2-p38alpha MAPK-MAPKAP-K2-HSP27 pathway[J]. Cell Signal, 2006 , [Epub ahead of print]
[26]. Abdollahi T, Robertson NM, Abdollahi A, et al. Inhibition of TRAIL-induced apoptosis by IL-8 is mediated by the p38-MAPK pathway in OVCAR3 cells [J]. Apoptosis, 2005, 10(6): 1383-1393
[27]. Pfannenschmid F, Wimmer VC, Rios RM, et al. Chlamydomonas DIP13 and human NA14: a new class of proteins associated with microtubule structures is involved in cell division[J]. J Cell Sci, 2003 , 116(Pt 8): 1449-1462
[28]. Liu J, Yao F, Wu R, Morgan M, Mediation of the DCC apoptotic signal by DIP13 alpha[J].J Biol Chem, 2002 , 277(29): 26281-26285
[29]. Neznanov N, Neznanova L, Kondratov RV, et al. Dominant negative form of signal-regulatory protein-alpha (SIRPalpha /SHPS-1) inhibits tumor necrosis factor-mediated apoptosis by activation of NF-kappa B[J]. J Biol Chem, 2003 , 278(6): 3809-3815
[30]. Zolezzi F, Linn S.Studies of the murine DDB1 and DDB2 genes [J]. Gene, 2000 , 245(1): 151-159
[31]. Tong JH, Fant X, Benoit G, et al. Genomic organization of the JEM-1 (BLZF1) gene on human chromosome 1q24: molecular cloning and analysis of its promoter region[J], Genomics, 2000 , 69(3): 380-390
[32]. Duprez E, Tong JH, Derre J, et al. JEM-1, a novel gene encoding a leucine-zipper nuclear factor upregulated during retinoid-induced maturation of NB4 promyelocytic leukaemia[J]. Oncogene, 1997, 14(13): 1563-1570
[33]. Klostermann A, Lutz B, Gertler F,et al. The orthologous human and murine semaphorin 6A-1 proteins (SEMA6A-l/Sema6A-1) bind to the enabled/vasodilator-stimulated phosphoprotein-like protein (EVL) via a novel carboxyl-terminal zyxin-like domain [J]. J Biol Chem, 2000, 275(50): 39647-39653
[34]. Okino K , Konishi H , Doi D , et al.Up-regulation of growth factor receptor-bound protein 10 in cervical squamous cell carcinoma [J]. Oncol Rep, 2005 , 13(6): 1069-1074
[35]. Langlais P, Dong LQ, Ramos FJ, et al.Negative regulation of insulin-stimulated mitogen-activated protein kinase signaling by Grb10 [J]. Mol Endocrinol, 2004 , 18(2): 350-358
[36]. Zhao R, Fu X, Li Q, et al. Specific interaction of protein tyrosine phosphatase-MEG2 with phosphatidylserine [J]. J Biol Chem, 2003, 278(25): 22609-22614.
[1]. Kaliberov SA, Kaliberova LN, Stockard CR,et al. Buchsbaum DJ. Adenovirus- mediated FLT1 -targeted proapoptotic gene therapy of human prostate cancer[J]. Mol Then 2004, 10(6): 1059-1070
[2]. Reddy RM, Tsai WS, Ziauddin MF, et al. Cisplatin enhances apoptosis induced by a tumor-selective adenovirus expressing tumor necrosis factor-related apoptosis-inducing ligand[j] J Thorac Cardiovasc Surg, 2004, 128(6): 883-891
[3]. Jacob D, Davis J, Schumacher G, et al. Adenoviral vector expressing the TRAIL gene driven by the hTERT promoter[J]. Z Gastroenterol, 2004, 42( 12): 1363-1370
[4]. Chang JY, Zhang X, Komaki R, et al. Tumor-specific apoptotic gene targeting overcomes radiation resistance in esophageal adenocarcinoma[J]. Int J Radiat Oncol Biol Phys, 2006, 64(5): 1482-1494
[5]. Lane D, Cote M, GrondinR, etal. Acquired resistance to TRAIL-induced apoptosis in human ovarian cancer cells is conferred by increased turnover of mature caspase-3[J]. Mol Cancer Ther, 2006, 5(3): 509-521
[6]. Wei Q. Pitx2a binds to human papillomavirus type 18 E6 protein and inhibits E6-mediated P53 degradation in HeLa cells[J]. J Biol Chem, 2005 , 280(45): 37790-37797
[7]. Stewart D, Ghosh A, Matlashewski G. Involvement of nuclear export in human papillomavirus type 18 E6-mediated ubiquitination and degradation of p53[J]. J Virol, 2005, 79(14): 8773-8783
[8]. Zhang HM, Yuan J, Cheung P, etal. Gamma interferon-inducible protein 10 induces HeLa cell apoptosis through a p53-dependent pathway initiated by suppression of human papillomavirus type 18 E6 and E7 expression., 2005, 25(14): 6247-6258
[9]. Hoμgardy BM, Maduro JH, van der Zee AG, et al. Proteasome inhibitor MG132 sensitizes HPV-positive human cervical cancer cells to rhTRAIL-induced apoptosis[J]. Int J Cancer, 2006, 118(8): 1892-1890
[10].Flahaut M, Muhlethaler-Mottet A, Auderset K, et al. Persistent inhibition of FLIP(L) expression by lentiviral small hairpin RNA delivery restores death-receptor-induced apoptosis in neuroblastoma cells[J]. Apoptosis 2006, 11(2): 255-263
[11]. Pelli N, Torre F, Delfino A, et al. Soluble tumor necrosis factor-related ligand ( TRAIL) levels and kinetics during antiviral treatment in chronic hepatitis C[J], J Interferon Cytokine Res, 2006 , 26(2): 119-123
[12]. Han J, Goldstein LA, Gastman BR, et al. Interrelated Roles for Mcl-1 and BIM in Regulation of TRAIL-mediated Mitochondrial Apoptosis[J]. J Biol Chem, 2006, 281(15): 10153-10163
[13] .MacFarlane M, Ahmad M, Srinivasula SM, etal. Identification and olecular cloning of two novel receptors for the cytotoxic ligand TRAIL[J]. J Biol Chem, 1997 , 272(41): 25417-25420
[14] .ScreatonG. R., Mongkolsapaya J., XuX. N., etal. TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL[J]. Curr. Biol, 1997, 7: 693-696
[15] .Degli-Esposti M. A., Smolak P. J., WalczakH., etal. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family[J]. J. Exp. Med., 1997, 186: 1165-1170
[16]. Degli-Esposti M. A., Doμgall W. C, Smolak P. J., etal. The novel receptor TRAIL-R4 induces NF-κB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain [J]. Immunity, 1997, 7: 813-820
[17] .Anan A, Baskin-Bey ES, Bronk SF, et al. Proteasome inhibition induces hepatic stellate cell apoptosis. Hepatology, 2006 , 43(2): 335-344
[18] Jurewicz A, Matysiak M, Andrzejak S, et al. TRAIL-induced death of human adult oligodendrocytes is mediated by JNK pathway[J]. Glia, 2006, 53(2): 158-66 2006, 54(4): 338-343
[19] .Shetty S, Graham BA, Brown JG, et al. Transcription factor NF-kappaB differentially regulates death receptor 5 expression involving histone deacetylase 1[J]. Mol Cell Biol,, 2005, 25(13): 5404-5416
[20]. Horinaka M, Yoshida T, Shiraishi T, et al. The combination of TRAIL and luteolin enhances apoptosis in human cervical cancer HeLa cells[J]. Biochem Biophys Res Commun., 2005, 333(3): 833-838
[21]. Shi RX, Ong CN, Shen HM. Protein kinase C inhibition and x-linked inhibitor of apoptosis protein degradation contribute to the sensitization effect of luteolin on tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in cancer cells[J]. Cancer Research. 2005, 65(17): 7815-7823
[22]．朱琳，李慧荣，吴建，等．宫颈癌细胞TRAIL死亡受体和诱骗受体表达的研究[J]．现代妇产科进展，2005，14，4：277-280
[23]. Kim CY, Jeong M, Mushiake H, et al. Cancer gene therapy using a novel secretable trimericTRAIL[J]. GeneTher, 2006, 13(4): 330-338
[24]. Elizabeth Tafolla, Shaohui Wang, Benita Wong, et al. KapilaJNK1 and JNK1 Oppositely Regulate p53 in Signaling Linked to Apoptosis Triggered by an Altered FibronectinMatrix[J]. J. Biol. Chem, 2005, 280(1): 19992-19999
[1]. Cmolak PJ, S.R., Schooley, et al. Identification and characterization of a new member of the TNF family that induces apoptosis[J]. Immunity , 1995, 3: 673-682
[2]. Pitti, R. M. , Marsters, et al. Induction ofapoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family[J]. J. Biol, 1996, 271: 12687-12690
[3]. Cha SS, Shin HC, Choi KY, et al. Purification and crystallization of recombinant human TRAIL[J]. Acta Crystallogr D Biol Crystallogr, 1999, 55(5): 1101-1104
[4]. Wang SH, Cao Z, Wolf JM, et al. Death ligand tumor necrosis factor-related apoptosis-inducing ligand inhibits experimental autoimmune thyroiditis. Endocrinology [J]. 2005 , 146(11): 4721-4726
[5]. Daniels RA, Turley H, Kimberley FC, et al. Expression of TRAIL and TRAIL receptors in normal and malignant tissues[J]. Cell Res, 2005, 15(6): 430-438
[6]. Song CJ, Liu XS, Zhu Y, et al. and DR5 in kidney and serum from patients receiving renal transplantation[J]. Transplant Proc, 2004, 36(5): 1340-1343
[7]. Pan G, O'Rourke K, Chinnaiyan AM, et al. Dixit VM. The receptor for the cytotoxic ligandTRAIL. Science[J]. 1997 , 4, 276(5309): 111-113
[8]. Truneh A, Sharrna S, Silverman C , et al. Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor[J]. , 2000, 28, 275(30): 23319-23325
[9]. Abdollahi T. Potential for TRAIL as a therapeutic agent in ovarian cancer[J]. Vitam Horm, 2004, 67:347-364
[10]. Kaliberov SA, Buchsbaum DJ, et al. Gene delivery and gene therapy of prostate cancer[J]. Expert Opin Drμg Deliv, 2006, 3(1): 37-51
[11]. Riccioni R, Pasquini L, Mariani G, et al. Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL[J]. Nat Med, 2001, 7(6): 680-686
[12]．张智峰，牛光明，宋来君，等．肿瘤坏死因子相关凋亡诱导配体诱导人 脑胶质瘤细胞凋亡作用的研究[J]．中国基层医药，2005，12(10)：1311-1313
[13]. Jurewicz A, Matysiak M, Andrzejak S, et al. TRAIL-induced death of human adult oligodendrocytes is mediated by YNK pathway[J]. Glia. , 2006, 15, 53(2): 158-166
[14]. Wang G, Ahmad KA, Ahmed K, et al. Role of protein kinase CK2 in the regulation of tumor necrosis factor-related apoptosis inducing ligand-induced apoptosis in prostate cancercells[J]. Cancer Res, 2006, 15, 66(4): 2242-2249
[15]. Shankar S, Singh TR, Fandy TE, et al. Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways[J]. Int J Mol Med, 2005, 16(6): 1125-1138
[16]. Abdollahi T, Robertson NM, Abdollahi A , et al. Inhibition of TRAIL-induced apoptosis by IL-8 is mediated by the p38-MAPK pathway in OVCAR3 cells[J]. Apoptosis, 2005, 10(6): 1383-1393
[17]. Yibin Deng, Yahong Lin, and Xiang wei Wu. TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO[J]. Gene Development, 2002, 16:33-45
[18]. Griffith TS, Rauch CT, Smolak PJ, et al. Functional analysis of TRAIL receptors usingmonoclonal antibodies[J]. J Immunol, 1999, 1, 162(5): 2597-2605
[19]. Leverkus M, Neumann M, Mengling T, et al. Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes[J]. Cancer Res, 2000, 1, 60(3): 553-559
[20]. Zhang XD, Franco AV, Nguyen T, et al. Differential localization and regulation of death and decoy receptors for TNF-related apoptosis-inducing ligand (TRAIL) inhuman melanomacells[J]. J Immunol, 2000, 15, 164(8): 3961-3970
[21]. Kuang AA, Diehl GE, Zhang J, et al. FADD is required for DR4- and DR5-mediated apoptosis: lack of TRAIL-induced apoptosis in FADD-deficient mouse embryonic fibroblasts[J]. J BiolChem, 2000, 18, 275(33): 25065-2508
[22]. Song JH, Bellail A, Tse MC, et al. Human astrocytes are resistant to Fas ligand and tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis[J]. J Neurosci, 2006, 22, 26(12): 3299-3308
[23]. Zhang XD, Wu JJ, Gillespie S , etal. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin[J]. Clin Cancer Res, 2006, 15, 12(4): 1355-1364
[24].Han J, Goldstein LA, Gastman BR, et al. Interrelated Roles for Mcl-1 and BIM in Regulation of TRAIL-mediated Mitochondrial Apoptosis[J]. J Biol Chem, 2006, 14, 281(15): 10153-10163
[25] .MacFarlane M, Merrison W, et al. Bratton SB, Cohen GM. Proteasome-mediated degradation of Smac during apoptosis: XIAP promotes Smac ubiquitination in vitro[J]. J Biol Chem. 2002 Sep 27;277(39): 36611-3616.
[26] .Kontny HU, Hammerle K, Klein R, et al. Sensitivity of Ewing's sarcoma to TRAIL-induced apoptosis[J]. Cell Death Differ, 2001, 8(5): 506-514
[27] .MitsiadesN, Mitsiades CS, Poulaki V, et al. Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells[J]. Blood, 2002, 15, 99(6): 2162-2171
[28] .Mitsiades N, Poulaki V, Mitsiades C, etal. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5[J]. Cancer Res. , 2001, 15, 61(6): 2704-2712
[29].Petak I, Vernes R, Szucs KS, et al. A caspase-8-independent component in TRAIL/Apo-2L-induced cell death in human rhabdomyosarcoma cells[J]. Cell Death Differ. , 2003 , 10(6): 729-739
[30] .Petak I, Douglas L. Tillman DM, et al. Pediatric rhabdomyosarcoma cell lines are resistant to Fas-induced apoptosis and highly sensitive to TRAIL-induced apoptosis[J]. Clin Cancer Res. , 2000 , 6(10): 4119-4127
[31]. Saitou Y, Shiraki K, Yamanaka T, et al. Augmentation of tumor necrosis factor family-induced apoptosis by E3330 in human hepatocellular carcinoma cell lines via inhibition of NF kappa B[J]. World J Gastroenterol, 2005, 28, 11(40): 6258-6261
[32].Tafuku S, Matsuda T, Kawakami H et, et al. Potential mechanism of resistance to TRAIL-induced apoptosis in Burkitt's lymphoma[J]. Eur J Haematol, 2006, 76(1): 64-74
[33] .Tanaka H, FujitaN, TsuruoT, etal. 3-Phosphoinositide-dependent protein kinase-1-mediated IkappaB kinase beta (IkkB) phosphorylation activates NF-kappaB signaling[J]. J Biol Chem, 2005, 9, 280(49), 40965-40973
[34] .Kumari AL, Ali AM, Das S, et al. Role of STAT3 and NFkappaB signaling in the serum factor-induced apoptosis in AK-5 cells[J]. Biochem Biophys Res Commun. , 2005, 28, 336(3): 860-867
[35] .Lakshmikanthan V, Kaddour-Djebbar I, Lewis RW, et a.SAHA-sensitized prostate cancer cells to TNFalpha-related apoptosis-inducing ligand (TRAIL): Mechanisms leading to synergistic apoptosis[J]. Int J Cancer, 2006, 119(1): 221-228
[36].Yamaguchi Y, ShirakiK, Fuke H, etal. Targeting of X-linked inhibitor of apoptosis protein or survivin by short interfering RNAs sensitize hepatoma cells to TNF-related apoptosis-inducing ligand- and chemotherapeutic agent-induced cell death[J]. Oncol Rep, 2005, 14(5): 1311-1316
[37]. Inoue T, Shiraki K, Fuke H, et al. Proteasome inhibition sensitizes hepatocellular carcinoma cells to TRAIL by suppressing caspase inhibitors and AKT pathway[J]. Anticancer Drugs, 2006, 17(3): 261-268
[38].Enokimura N, Shiraki K, Kawakita T, et al. Vitamin K analog (compound 5) induces apoptosis in human hepatocellular carcinoma independent of the caspase pathway[J]. Anticancer Drugs, 2005 , 16(8): 837-844
[39].Han J, Goldstein LA, Gastman BR, etal. Rabinowich H. Interrelated Roles for Mcl-1 and BIM in Regulation of TRAIL-mediated Mitochondrial Apoptosis[J]. J Biol Chem, 2006 , 14;281(15): 10153-10163
[40].Ravi R, Fuchs EJ, Jain A, et al. Resistance of cancers to immunologic cytotoxicity and adoptive immunotherapy via X-linked inhibitor of apoptosis protein expression and coexisting defects in mitochondrial death signaling[J]. Cancer Res, 2006 , 66(3): 1730-1739
[41] .KM, Tan M, Sun Y, et al. A small molecule Smac-mimic compound induces apoptosis and sensitizes TRAIL- and etoposide-induced apoptosis in breast cancer cells[J]. Oncogene, 2005, 24(49): 7381-7388
[42].Hinz S, Trauzold A, Boenicke L, et al. Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis[J]. Oncogene, 2000, 16, 19(48): 5477-5486
[43] .Zhang XD, Zhang XY , Gray CP, et al. Tumor necrosis factor-re-lated apo ptos is-inducing ligand-induced apoptosis of human melanolYlais r-ulated by srnac /DiABLO release from m / tochondna[J]. Cancer Res, 2001, 61(19): 7339-7348
[44] .Munshi A, McDonnell TJ, Meyn RE, et al. Chemotherapeutic agents enhance TRAIL-induced apoptosis in prostate cancer cells. Cancer Chemother Pharmacol[J]. 2002, 50(1): 46-52
[45].KangJ, BuJ, Hao Y, et al. Subtoxic concentration of doxorubicin enhances TRAIL-induced apoptosis in human prostate cancer cell line LNCaP[J]. Prostate Cancer Prostatic Dis. , 2005, 8(3): 274-279
[46] .LeBlancH, LawrenceD, VarfolomeevE, et al. Turnor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homologBax[J]. Nat Med, 2002, 8(3): 274—281
[47] .Kandasamy K, Srinivasula SM , Alnemri ES, et al. Involvement of proapo ptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apo ptos is: differential regulation of cytochmmec and Smac / DIABLO release[J]. Cancer Res, 2003, 63(7): 1712-1721
[48] .Kim M, Jung SO, Park K, et al. Detection of Bax protein conformational change using a surface plasmon resonance imaging-based antibody chip[J]. Biochem Biophys Res Commun, 2005, 30, 338(4): 1834-1838
[49] .Baillat G, Garrouste F, Remacle-Bonnet M, et al. Bcl-xL/Bax ratio is altered by IFNgamma in TNFalpha- but not in TRAIL-induced apoptosis in colon cancer cell line[J]. Biochim Biophys Acta, 2005, 15, 1745(1): 101-110
[50].Wendt J, von Haefen C, Hemmati P, et al. TRAIL sensitizes for ionizing irradiation-induced apoptosis through an entirely Bax-dependent mitochondrial cell death pathway[J]. Oncogene, 2005, 9, 24(25): 4052-4064
[51].von Haefen C, Gillissen B, Hemmati PG, et al. Multidomain Bcl-2 homolog Bax but not Bak mediates synergistic induction ofapoptosis by TRAIL and 5-FU throμtgh the mitochondrial apoptosis pathway[J]. Oncogene, 2004, 28, 23(50): 8320-8332
[52]. Beresford SA, Davies MA, Gallick GE, et al. Donato NJ. Differential effects of phosphatidylinositol-3/Akt-kinase inhibition on apoptotic sensitization to cytokines in LNCaP and PCc-3 prostate cancer cells[J]. J Interferon Cytokine Res, 2001, 21(5): 313-322
[53]. Yoshida S, Narita T, Koshida S, et al. TRAIL/Apo2L ligands induce apoptosis in malignant rhabdoid tumor cell lines[J]. Pediatr Res, 2003, 54(5): 709-717
[54]. Dubska L, Andera L, Sheard MA, et al. HER2 signaling downregulation by trastuzumab and suppression of the PI3K/Akt pathway: an unexpected effect on TRAIL-inducedapoptosis[J]. FEBS Lett, 2005, 1, 579(19): 4149-4158
[55]. Tamai M, Kawakami A, Tanaka F, et al. Significant inhibition of TRAIL-mediated fibroblast-like synovial cell apoptosis by IFN-gamma throμgh JAK/STAT pathway by translational regulation[J]. J Lab Clin Med, 2006, 147(4): 182-190
[56]. Yamai M, Kawakami A, Tanaka F. Significant inhibition of TRAIL-mediated fibroblast-like synovial cell apoptosis by IFN-gamma throμgh JAK/STAT pathway by translational regulation[J]. J Lab Clin Med, 2006, 147(4): 182-190
[57]．李小安，房殿春，司佩任，等．TRAIL诱导肝癌细胞系SMMC—7721的凋亡作用[J]．世界华人消化杂志[J]。2003，11，9：1369-1371
[58]．何松青，陈彦，陈孝平．TRAIL的抗肝细胞癌作用研究[J]．中华肝胆外科杂志[J]．2003，9，11：670-673
[59]．杨柳芹，房殿春．α-生育酚对TRAIL诱导胃癌细胞凋亡的影响及机制[J]．解放军医学杂志[J]．2005，30，9：779-781
[60]. Ma H, Liu Y, Liu S, et al. Oral adeno-associated virus- TRAIL gene therapy suppresses human hepatocellular carcinoma growth in mice[J]. Hepatology, 2005, 42(6): 1355-1363
[61]. Kaliberov SA, Kaliberova LN, Stockard CR, et al. Buchsbaum DJ. Adenovirus-mediated FLT1 -targeted proapoptotic gene therapy of human prostate cancer[J]. Mol Ther, 2004, 10(6): 1059-1070
[62].Kazhdan I, Marciniak RA, et al. Death receptor 4 (DR4) efficiently kills breast cancer cells irrespective of their sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)[J]. Cancer Gene Ther, 2004, 11(10):691-698
[63 ]. Jacob D, Davis J, Schumacher G, et al. Adenoviral vector expressing the TRAIL gene driven by the hTERT promoter[J]. Z Gastroenterol, 2004, 42(12): 1363-1370
[64]. Reddy RM, Tsai WS, Ziauddin MF, et al. Cisplatin enhances apoptosis induced by a tumor-selective adenovirus expressing tumor necrosis factor-related apoptosis-inducing ligand[J]. J Thorac Cardiovasc Surg, 2004, 128(6): 883-891
[65] .Shankar S, Chen X, Srivastava RK. Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo[J]. Prostate, 2005, 1, 62(2): 165-186
[66].Nagane M, Pan G, WeddleJJ. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo[J]. cancer Res, 2000, 15, 60(4): 847-853
[67]. Singh TR , Shankar S, Chen X, et al. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor—related apoptosis-inducing ligand/ApoL-2 ligand on apoptosis and on regression of breast carcino-ma in vivo[J]. Cancer Res, 2003, 63(17): 5390-5400
[68]. Ahucci L, Rossin A, Raffelsberger W, et al. Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL Nat Med, 2001, 7(6): 680—686
[69] .Keane MM, Rubinstein Y, CuelloM. Inhibition of NF-kappaB activity enhances TRAIL mediated apoptosis in breast cancer cell lines. Breast Cancer Res Treat[J]. 2000 Nov;64(2): 211-219.
[70] .Chopin V, SlomiannyC, Hondermarck H. Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21(wafl)[J]. ExpCellRes, 2004, 15, 298(2): 560-573
[71]. Walczak H, Bouchon A, Stahl H. Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2-or Bcl-xL-overexpressing hemotherapy-resistant tumor cells[J]. Cancer Res, 2000, 1, 60(11): 3051-3057
[72]. Wang S, El-Deiry WS, et al. Inducible silencing of KILLER/DR5 in vivo promotes bioluminescent colon tumor xenograft growth and confers resistance to chemotherapeutic agent5-fluorouracil[J]. Cancer Res, 2004, 64(18): 6666-6672.
[73]. Ashkenazi, A., Pai, et al. Safety and antitumor activity of recombinant solubleApo2 ligand[J]. J. Clin. Invest, 1999, 104, 155-162
[74]. Jin TG, Kurakin A, Benhaga N. Fas-associated protein with death domain (FADD)-independent recruitment of c-FLIPL to death receptor 5[J]. J Biol Chem, 2004, 31, 279(53): 55594-55601
[75]. Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosisfactor-related apoptosis-inducing ligand in vivo[J]. Nat. Med. (1999)5, 157-163
[76]. Horinaka M, Yoshida T, Shiraishi T, et al. The combination of TRAIL and luteolin enhances apoptosis in human cervical cancer HeLa cells[J]. Biochem Biophys Res Commun, 2005, 333(3): 833-838
[77]. Shi RX, Ong CN. Shen HM. Protein kinase C inhibition and x-linked inhibitor of apoptosis protein degradation contribute to the sensitization effect of luteolin on tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in cancer cells[J]. Cancer Res, 2005, 65(17): 7815-7823
[78]．朱琳，李慧荣，吴建，等．宫颈癌细胞TRAIL死亡受体和诱骗受体表达的研究[J]．现代妇产科进展，2005，14，4：277-280
[79]. Kim CY, Jeong M, Mushiake H, et al. Cancer gene therapy using a novel secretable trimeric TRAIL[J]. Gene Ther, 2006, 13(4): 330-338
[80]. Hougardy BM, Maduro JH, van der Zee AG, et al. Proteasome inhibitor MG132 sensitizes HPV-positive human cervical cancer cells to rhTRAIL-induced apoptosis[J]. Int J Cancer, 2006, 15, 118(8): 1892-1900
[81] .Garnett TO, Filippova M. Duerksen-Hughes PJ, et al. Accelerated degradation of FADD and procaspase 8 in cells expressing human papilloma virus 16 E6 impairs TRAIL-mediated apoptosis[J]. Cell Death Differ, 2006, 10, [Epub ahead of print]
[82].Lee MW, Bach JH, Lee HJ, et al. The activation of ERK1/2 via a tyrosine kinase pathway attenuates TRAIL-induced apoptosis in HeLa cells[J]. Cancer Invest, 2005, 23(7): 586-592
[2]. Liabakk, N. B, Sundan, et al.characterization and use of monoclonal antibodies against TRAIL: measurementof TRAIL by ELISA. J. Immunol[J]. Methods, 2002, (259): 119-128
[3]．史治宙，宋朝君，黄威权，等．肿瘤坏死因子相关凋亡诱导配体在外周血单个核细胞中的表达[J]．解剖学杂志，2005，28(1)：29-30
[4]．陈江，陈晓春，曾甫清，等．TRAIL受体在前列腺癌中的表达[J]．现代泌尿外科杂志，2004，9(1)：3-5
[5]．李春梅，彭芝兰，杨开选，等．TRAIL及其受体和Fas—L在卵巢癌组织中的表达[J]．四川大学学报：医学版，2005，36(3)：341-343
[6]．阎庆辉，刘津，张国建，等．蔡建辉肿瘤相关凋亡诱导配体、Survivin、Caspase-3和NF-κB在大肠癌中的表达[J]．中华实验外科杂志，2005，22(10)：1197-1197
[7]．宋朝君，刘雪松，陈丽华，等．TRAIL及其受体在正常心脏组织的免疫组织化学定位[J]．心脏杂志，2003，15(6)：490-492
[8]．僧靖静，张云汉，高冬玲．TRAIL、Survivin mRNA表达与胃癌凋亡发生的相关关系[J]．河南大学学报：医学版，2005，24(1)：25-28
[9]．任秀花，张华，吴红霞，等．食管癌发生发展过程中TRAIL和Survivin蛋白的表达研究[J]．河南肿瘤学杂志，2005，18(5)：305-306
[10]. Yao GH, Hou YY . Recent advances for research on anti-tumor effects of TNF-related apoptosis-inducing ligand[J]. Wei Sheng Yan Jiu, 2006 , 35(1): 115-117
[11]. Pathil A, Armeanu S, Venturelli S, et al. HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL[J]. Hepatology, 2006, 43(3): 425-434
[12]. Vitale M, Gobbi G, Mirandola P, et al. TNF-RELATED APOPTOSIS-inducing ligand (TRAIL) and erythropoiesis: a role for PKC(epsilon)[J]. Eur J Histochem, 2006, 50(1): 15-18
[13]. Pathil A, Armeanu S, Venturelli S, et al. HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity toTRAIL[J]. Hepatology, 2006, 43(3): 425-434
[14]. Chang JY, Zhang X, Komaki R, et al. Tumor-specific apoptotic gene targeting overcomes radiation resistance in esophageal adenocarcinoma[J]. Int J Radiat Oncol Biol Phys, 2006, 64(5): 1482-1494
[15]. Haines JF, TRAIL IA, Nuttall D, et al. The results of arthroplasty in osteoarthritis of the shoulder[J]. J Bone Joint Surg Br, 2006, 88(4): 496-501
[16]．梁晓红，孙汶生，高立芬，等．乙型肝炎病毒X蛋白调节TRAIL诱导的肝细胞凋亡[J]．中国科学：C辑，2005，35(1)：59-67
[17]．杜秀敏，游木荣，齐法莲，等．TRAIL及NF—kB在骨肉瘤中的表达、及其意义标记[J]．免疫分析与临床，2005，12(2)：65-66，69
[18]．何超，胡文献，胡晓彤，等．γ-干扰素加强TRAIL抑制人大肠癌细胞株作用的研究[J]．中国病理生理杂志，2006，22(2)：365-367
[19]．张智峰，牛光明，宋来君，等．肿瘤坏死因子相关凋亡诱导配体诱导人脑胶质瘤细胞凋亡作用的研究[J]．中国基层医药，2005，12(10)：1311-1313
[20]．范清林，魏伟，邹文艺，等．人TRAIL基因的克隆、表达、纯化及对人A549细胞的抗肿瘤活性作用[J]．中国药理学通报，2006，22(2)：228-233
[21]．周莉，闫明霞，姚明，等．转染TRAIL的内皮祖细胞对人卵巢癌裸鼠皮下移植瘤的抑制作用[J]．癌症，2005，24(11)：1312-1316
[22]．刘培淑，白琴，侯萍，等．TRAIL对3AO裸鼠移植瘤治疗作用的实验研究[J]．现代妇产科进展，2004，13(2)：114-116，119
[23]．王正兵，贾筱琴，陈兵，等．TRAIL真核表达．质粒的构建及抑制肝癌生长的实验研究[J]．中国普外基础与临床杂志，2005，12(3)：261-264
[24]. Kaliberov SA , Kaliberova LN, Stockard CR, et al . Buchsbaum DJ. Adenovirus-mediated FLT1-targeted proapoptotic gene therapy of human prostate cancer[J]. Mol Yher, 2004, 10(6): 1059-1070
[25]. Reddy RM, Tsai WS, Ziauddin MF, et al. Cisplatin enhances apoptosis induced by a tumor-selective adenovirus expressing rumor necrosis factor-related apoptosis-inducing ligand[J]. J Thorac Cardiovasc Surg, 2004, 128(6): 883-891
[26]. Jacob D, Davis J, Schumacher G, et al. Adenoviral vector expressing the TRAIL gene driven by the hTERT promoter[J]. Z Gastroenterol, 2004, 42(12): 1363-1370
[27]．李宁，范学工，人TRAIL分子的克隆、表达．及鉴定[J]．中国现代医学杂志，2004，14(3)：82-85
[28]．路丽明，李宁丽，沈佰华，等．TRAIL分子胞外区基因工程蛋白的制备与鉴定[J]．中国实验诊断学，2003，7(6)：477-479
[29]. Li HM, Song TB, Yu YC, et al. Construction of TRAIL gene eukaryotic expression vector modulated by hTERT gene core promoter and its effect on apoptosis of ovarian cancer cells[J]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, 2006, 22(2): 243-246
[30]．王梁华，焦炳华．人TRAIL在毕氏酵母表达系统中的表达[J]．细胞与分子免疫学杂志，2000，16(5)：420-424
[1]．李小安，房殿春，司佩任，等．TRAIL诱导肝癌细胞系SMMC—7721的凋亡作用[J]．世界华人消化杂志，2003，11，9：1369-1371
[2]．何松青，陈彦，陈孝平．TRAIL的抗肝细胞癌作用研究[J]．中华肝胆外科杂志，2003，9，11：670-673
[3]．杨柳芹，房殿春．α-生育酚对TRAIL诱导胃癌细胞凋亡的影响及机制[J]．解放军医学杂志，2005，30，9：779-781
[4]. Ma H, Liu Y, Liu S, et al. Oral adeno-associated virus- TRAIL gene therapy suppresses human hepatocellular carcinoma growth in mice[J]. Hepatology, 2005, 42(6): 1355-1363
[5]. Kaliberov SA, Kaliberova LN, Stockard CR, et al. Adenovirus-mediated FLT1-targeted proapoptotic gene therapy of human prostate cancer[J], 2004, 10(6): 1059-1070
[6]. Reddy RM, Tsai WS, Ziauddin MF, et al. Cisplatin enhances apoptosis induced by a tumor-selective adenovirus expressing tumor necrosis factor-related apoptosis-inducing ligand[J]. J Thorac Cardiovasc Surg, 2004, 128(6): 883-891
[7]. Kazhdan I, Marciniak RA. Death receptor 4 (DR4) efficiently kills breast cancer cells irrespective of their sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)[J]. Cancer Gene Ther, 2004 , 11(10):691-698
[8]. Shankar S, Chen X, Srivastava RK. Effects of sequential treatments with chemotherapeutic drμgs followed by TRAIL on prostate cancer in vitro and in vivo[J]. Prostate, 2005, 1, 62(2): 165-186
[9]. Jacob D, Davis J, Schumacher G, et al. Adenoviral vector expressing the TRAIL gene driven by the hTERT promoter[J]. Z Gastro- enterol, 2004, 42(12): 1363-1370
[10]．朱琳，李慧荣，吴建，等．宫颈癌细胞TRAIL死亡受体和诱骗受体表达的研究[J]．现代妇产科进展，2005，14，4：277-280
[11]. Xiang M, Lin YZ, Zhu SL. MTT colorimetric assay for the biological actibity of hepatic stimulator substance[J]. Xin Xiao Hua Bing Xue Za zhi, 1996, 4: 428-431
[12]. Wang CY, James E, Jim L, et al. Spontaneous apotosis in human colon tumor cell lines and the relation of WT p53 to apoptosis[J]. Chinese Medical Journal, 1996, 109:537-541
[13]. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group[J]. J Natl Cancer Inst, 1995, 87(11): 796-802
[14]. Lombard I, Vincent-Salomon A, Validire P, et al. Human papillomavirus genotype as a major determinant of the course of cervical[J]. J Clin Oncol, 1998, 16(8): 2613-2619
[15]. Liss J, Emerich J, Lukaszuk K, et al. The use of PCR technique in the evaluation of the frequency of HPV infection in vulvar and cervical carcinoma[J] Ginekol Pol, 1998, 69(5): 330-334
[16]. Arakawa K, Ishihara T, Auto M, et al. Action of novel antidiabetic thiazolidinedione, T-174, in animals of non-insulin-dependent diabetesmellitus(NIDDM) and in cultured muscle cells[J]. Br J Pharmacol, 1998, 125:429-436
[17]. Purrello F, Gullo D, Brunetti A, et al. Direct effects of biguanides on glucose utilization invitro[J]. Metabolism, 1987, 36(8): 774-776
[18]．汪承亚，盛瑞兰．细胞凋亡与肿瘤[J]．国外医学生理、病理科学与临床分册，1996，16(4)：291-293
[1]. Pitti RM , Marsters SA, Ruppert S, et al. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine Family[J]. J Biol Chem, 1996, 271(22): 12687—12690
[2]. Choi E, Kim Y, Kim K. The Combination of TRAIL Treatment and Cancer Cell Selective Expression of TRAIL-Death Receptor DR4 Induces Cell Death in TRAIL-Resistant Cancer Cells[J]. Yonsei Med J, 2006, 28;47(1): 55-62.
[3]. Deeb DD, Jiang H, Gao X, et al. Chemosensitizationofhormone-refractory prostate cancer cells by curcumin to TRAIL-induced apoptosis[J]. J Exp Ther Oncol, 2005, 5(2): 81-91
[4]. Chang JY, Zhang X, Komaki R, et al. Tumor-specific apoptotic gene targeting overcomes radiation resistance in esophageal adenocarcinoma[J]. Int J Radiat Oncol Biol Phys, 2006, 64(5): 1482-1494.
[5]. Ortiz-Ferron G, Yait SW, Robledo G, et al. The mitogen-activated protein kinase pathway can inhibit TRAIL-induced apoptosis by prohibiting association of truncated Bid with mitochondria[J]. Cell Death Differ, 2006 , [Epub ahead of print]
[6]. Bollag DM and Edelstein SJ. Protein Methods[M]. Chapter2: protein extraction, Wiley-Liss, NewYork. 1991
[7]. Bradford MM. A rapid and sensitive method for the quantitation of microgram of protein utilizing the principle of protein—dye binding[J]. Anal Biochem, 1976, 72: 248～254.
[8]．钱小红，贺福初．蛋白质组学理论与方法[M]．科学出版社(北京)2003年6月，第一版
[9]. Parkin D M, Bray F, Ferlay J, et al. Estimating the world cancerburden: Globocan [J]. Int J Cancer, 2001, 94:153-156
[10]. Nicolas F S, AndreaT, ElianeDF, et al. Viralload as apredictor of the risk of cervical intraepithelial neoplasia[J]. Int J Cancer, 2003, 103:519-524
[11]. Silva D M , Eiben C'L, Fausch S C, et al. Cervical cancervaccines: emerging concepts and developments[J]. Cell Physiol, 2001, 186(2): 169-182
[12]. Burd E M. Human Papillomavirus and cervical cancer[J], clinMicrobiol Rev, 2o03, 16(1): 1-17
[13]. Horinaka M, Yoshida T, Shiraishi T, et al. The combination of TRAIL and luteolin enhances apoptosis in human cervical cancer HeLa cells[J]. Biochem Biophys Res Commun, 2005, 333(3): 833-838
[14]. Shi RX, Ong CN, Shen HM. Protein kinase C inhibition and x-linked inhibitor of apoptosis protein degradation contribute to the sensitization effect of luteolin on tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in cancer cells[J]. Cancer Res, 2005, 65(17): 7815-7823
[15]. Kim CY, Jeong M, Mushiake H, et al. Cancer gene therapy using a novel secretable trimeric TRAIL[J]. Gene Ther. 2006 , 13(4): 330-338
[16]．夏其昌，曾嵘等．蛋白质化学与蛋白质组学[M]．科学出版社(北京)2004年第一版
[17]. Herr I, Wilhelm D, Meyer E, et al. JNK/SAPK activity contributes to TRAIL-induced apoptosis[J]. Cell Death Differ, 1999, 6(2): 130-135
[18]. Mikami T, Koyama T, Koyama T, et al. C-jun N-terminal kinase activation is required for apoptotic cell death induced by TNF-related apoptosis-inducing ligand plus DNA-damaging agents in sarcoma cell lines[J]. Anticancer Res, 2006, 26(2A): 1153-1160
[19]. Vivo C, Liu W, Broaddus VC, et al. c-Jun N-terminal kinase contributes to apoptotic synergy induced by tumor necrosis factor-related apoptosis-inducing ligand plus DNA damage in chemoresistant, p53 inactive mesothelioma cells[J]. J Biol Chem, 2003, 278(28): 25461-25467
[20]. Kwon D, Cheong JH, Lee JC, et al. Lipopolysaccharides-activated human astroglioma cells induce apoptotic death of T-lymphocytes via c-Jun N-terminal kinases-dependent up-regulation of TRAIL[J]. Neurosci Res, 2006, 54(4): 338-343
[21]. JurewiczA, Matysiak M, Andrzejak S, et al. TRAIL-induced death of human adult oligodendrocytes is mediated by JNK pathway[J]. Glia, 2006, 53(2): 158-166
[22]. Aggarwal BB, Bhardwaj A, Aggarwal RS, et al. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies[J]. Anticancer Res, 2004, 24(5A): 2783-2840.
[23]. Puduvalli VK, Sampath D, Bruner JM, et al. TRAIL-induced apoptosis in gliomas is enhanced by Akt-inhibition and is independent of JNK activation[J]. Apoptosis, 2005, 10(1): 233-243
[24]. Yanase N, Hata K, Shimo K, et al.Requirement of c-Jun NH2-terminal kinase activation in interferon-alpha-induced apoptosis through upregulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in Daudi B lymphoma cells[J].Exp Cell Res, 2005 , 310(1): 10-21
[25]. Oncogene, 199, 14(13): 1563-1570Rousseau S, Dolado I, Beardmore V, et al. CXCL12 and C5a trigger cell migration via a PAKl/2-p38alpha MAPK-MAPKAP-K2-HSP27 pathway[J]. Cell Signal, 2006 , [Epub ahead of print]
[26]. Abdollahi T, Robertson NM, Abdollahi A, et al. Inhibition of TRAIL-induced apoptosis by IL-8 is mediated by the p38-MAPK pathway in OVCAR3 cells [J]. Apoptosis, 2005, 10(6): 1383-1393
[27]. Pfannenschmid F, Wimmer VC, Rios RM, et al. Chlamydomonas DIP13 and human NA14: a new class of proteins associated with microtubule structures is involved in cell division[J]. J Cell Sci, 2003 , 116(Pt 8): 1449-1462
[28]. Liu J, Yao F, Wu R, Morgan M, Mediation of the DCC apoptotic signal by DIP13 alpha[J].J Biol Chem, 2002 , 277(29): 26281-26285
[29]. Neznanov N, Neznanova L, Kondratov RV, et al. Dominant negative form of signal-regulatory protein-alpha (SIRPalpha /SHPS-1) inhibits tumor necrosis factor-mediated apoptosis by activation of NF-kappa B[J]. J Biol Chem, 2003 , 278(6): 3809-3815
[30]. Zolezzi F, Linn S.Studies of the murine DDB1 and DDB2 genes [J]. Gene, 2000 , 245(1): 151-159
[31]. Tong JH, Fant X, Benoit G, et al. Genomic organization of the JEM-1 (BLZF1) gene on human chromosome 1q24: molecular cloning and analysis of its promoter region[J], Genomics, 2000 , 69(3): 380-390
[32]. Duprez E, Tong JH, Derre J, et al. JEM-1, a novel gene encoding a leucine-zipper nuclear factor upregulated during retinoid-induced maturation of NB4 promyelocytic leukaemia[J]. Oncogene, 1997, 14(13): 1563-1570
[33]. Klostermann A, Lutz B, Gertler F,et al. The orthologous human and murine semaphorin 6A-1 proteins (SEMA6A-l/Sema6A-1) bind to the enabled/vasodilator-stimulated phosphoprotein-like protein (EVL) via a novel carboxyl-terminal zyxin-like domain [J]. J Biol Chem, 2000, 275(50): 39647-39653
[34]. Okino K , Konishi H , Doi D , et al.Up-regulation of growth factor receptor-bound protein 10 in cervical squamous cell carcinoma [J]. Oncol Rep, 2005 , 13(6): 1069-1074
[35]. Langlais P, Dong LQ, Ramos FJ, et al.Negative regulation of insulin-stimulated mitogen-activated protein kinase signaling by Grb10 [J]. Mol Endocrinol, 2004 , 18(2): 350-358
[36]. Zhao R, Fu X, Li Q, et al. Specific interaction of protein tyrosine phosphatase-MEG2 with phosphatidylserine [J]. J Biol Chem, 2003, 278(25): 22609-22614.
[1]. Kaliberov SA, Kaliberova LN, Stockard CR,et al. Buchsbaum DJ. Adenovirus- mediated FLT1 -targeted proapoptotic gene therapy of human prostate cancer[J]. Mol Then 2004, 10(6): 1059-1070
[2]. Reddy RM, Tsai WS, Ziauddin MF, et al. Cisplatin enhances apoptosis induced by a tumor-selective adenovirus expressing tumor necrosis factor-related apoptosis-inducing ligand[j] J Thorac Cardiovasc Surg, 2004, 128(6): 883-891
[3]. Jacob D, Davis J, Schumacher G, et al. Adenoviral vector expressing the TRAIL gene driven by the hTERT promoter[J]. Z Gastroenterol, 2004, 42( 12): 1363-1370
[4]. Chang JY, Zhang X, Komaki R, et al. Tumor-specific apoptotic gene targeting overcomes radiation resistance in esophageal adenocarcinoma[J]. Int J Radiat Oncol Biol Phys, 2006, 64(5): 1482-1494
[5]. Lane D, Cote M, GrondinR, etal. Acquired resistance to TRAIL-induced apoptosis in human ovarian cancer cells is conferred by increased turnover of mature caspase-3[J]. Mol Cancer Ther, 2006, 5(3): 509-521
[6]. Wei Q. Pitx2a binds to human papillomavirus type 18 E6 protein and inhibits E6-mediated P53 degradation in HeLa cells[J]. J Biol Chem, 2005 , 280(45): 37790-37797
[7]. Stewart D, Ghosh A, Matlashewski G. Involvement of nuclear export in human papillomavirus type 18 E6-mediated ubiquitination and degradation of p53[J]. J Virol, 2005, 79(14): 8773-8783
[8]. Zhang HM, Yuan J, Cheung P, etal. Gamma interferon-inducible protein 10 induces HeLa cell apoptosis through a p53-dependent pathway initiated by suppression of human papillomavirus type 18 E6 and E7 expression., 2005, 25(14): 6247-6258
[9]. Hoμgardy BM, Maduro JH, van der Zee AG, et al. Proteasome inhibitor MG132 sensitizes HPV-positive human cervical cancer cells to rhTRAIL-induced apoptosis[J]. Int J Cancer, 2006, 118(8): 1892-1890
[10].Flahaut M, Muhlethaler-Mottet A, Auderset K, et al. Persistent inhibition of FLIP(L) expression by lentiviral small hairpin RNA delivery restores death-receptor-induced apoptosis in neuroblastoma cells[J]. Apoptosis 2006, 11(2): 255-263
[11]. Pelli N, Torre F, Delfino A, et al. Soluble tumor necrosis factor-related ligand ( TRAIL) levels and kinetics during antiviral treatment in chronic hepatitis C[J], J Interferon Cytokine Res, 2006 , 26(2): 119-123
[12]. Han J, Goldstein LA, Gastman BR, et al. Interrelated Roles for Mcl-1 and BIM in Regulation of TRAIL-mediated Mitochondrial Apoptosis[J]. J Biol Chem, 2006, 281(15): 10153-10163
[13] .MacFarlane M, Ahmad M, Srinivasula SM, etal. Identification and olecular cloning of two novel receptors for the cytotoxic ligand TRAIL[J]. J Biol Chem, 1997 , 272(41): 25417-25420
[14] .ScreatonG. R., Mongkolsapaya J., XuX. N., etal. TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL[J]. Curr. Biol, 1997, 7: 693-696
[15] .Degli-Esposti M. A., Smolak P. J., WalczakH., etal. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family[J]. J. Exp. Med., 1997, 186: 1165-1170
[16]. Degli-Esposti M. A., Doμgall W. C, Smolak P. J., etal. The novel receptor TRAIL-R4 induces NF-κB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain [J]. Immunity, 1997, 7: 813-820
[17] .Anan A, Baskin-Bey ES, Bronk SF, et al. Proteasome inhibition induces hepatic stellate cell apoptosis. Hepatology, 2006 , 43(2): 335-344
[18] Jurewicz A, Matysiak M, Andrzejak S, et al. TRAIL-induced death of human adult oligodendrocytes is mediated by JNK pathway[J]. Glia, 2006, 53(2): 158-66 2006, 54(4): 338-343
[19] .Shetty S, Graham BA, Brown JG, et al. Transcription factor NF-kappaB differentially regulates death receptor 5 expression involving histone deacetylase 1[J]. Mol Cell Biol,, 2005, 25(13): 5404-5416
[20]. Horinaka M, Yoshida T, Shiraishi T, et al. The combination of TRAIL and luteolin enhances apoptosis in human cervical cancer HeLa cells[J]. Biochem Biophys Res Commun., 2005, 333(3): 833-838
[21]. Shi RX, Ong CN, Shen HM. Protein kinase C inhibition and x-linked inhibitor of apoptosis protein degradation contribute to the sensitization effect of luteolin on tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in cancer cells[J]. Cancer Research. 2005, 65(17): 7815-7823
[22]．朱琳，李慧荣，吴建，等．宫颈癌细胞TRAIL死亡受体和诱骗受体表达的研究[J]．现代妇产科进展，2005，14，4：277-280
[23]. Kim CY, Jeong M, Mushiake H, et al. Cancer gene therapy using a novel secretable trimericTRAIL[J]. GeneTher, 2006, 13(4): 330-338
[24]. Elizabeth Tafolla, Shaohui Wang, Benita Wong, et al. KapilaJNK1 and JNK1 Oppositely Regulate p53 in Signaling Linked to Apoptosis Triggered by an Altered FibronectinMatrix[J]. J. Biol. Chem, 2005, 280(1): 19992-19999
[1]. Cmolak PJ, S.R., Schooley, et al. Identification and characterization of a new member of the TNF family that induces apoptosis[J]. Immunity , 1995, 3: 673-682
[2]. Pitti, R. M. , Marsters, et al. Induction ofapoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family[J]. J. Biol, 1996, 271: 12687-12690
[3]. Cha SS, Shin HC, Choi KY, et al. Purification and crystallization of recombinant human TRAIL[J]. Acta Crystallogr D Biol Crystallogr, 1999, 55(5): 1101-1104
[4]. Wang SH, Cao Z, Wolf JM, et al. Death ligand tumor necrosis factor-related apoptosis-inducing ligand inhibits experimental autoimmune thyroiditis. Endocrinology [J]. 2005 , 146(11): 4721-4726
[5]. Daniels RA, Turley H, Kimberley FC, et al. Expression of TRAIL and TRAIL receptors in normal and malignant tissues[J]. Cell Res, 2005, 15(6): 430-438
[6]. Song CJ, Liu XS, Zhu Y, et al. and DR5 in kidney and serum from patients receiving renal transplantation[J]. Transplant Proc, 2004, 36(5): 1340-1343
[7]. Pan G, O'Rourke K, Chinnaiyan AM, et al. Dixit VM. The receptor for the cytotoxic ligandTRAIL. Science[J]. 1997 , 4, 276(5309): 111-113
[8]. Truneh A, Sharrna S, Silverman C , et al. Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor[J]. , 2000, 28, 275(30): 23319-23325
[9]. Abdollahi T. Potential for TRAIL as a therapeutic agent in ovarian cancer[J]. Vitam Horm, 2004, 67:347-364
[10]. Kaliberov SA, Buchsbaum DJ, et al. Gene delivery and gene therapy of prostate cancer[J]. Expert Opin Drμg Deliv, 2006, 3(1): 37-51
[11]. Riccioni R, Pasquini L, Mariani G, et al. Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL[J]. Nat Med, 2001, 7(6): 680-686
[12]．张智峰，牛光明，宋来君，等．肿瘤坏死因子相关凋亡诱导配体诱导人 脑胶质瘤细胞凋亡作用的研究[J]．中国基层医药，2005，12(10)：1311-1313
[13]. Jurewicz A, Matysiak M, Andrzejak S, et al. TRAIL-induced death of human adult oligodendrocytes is mediated by YNK pathway[J]. Glia. , 2006, 15, 53(2): 158-166
[14]. Wang G, Ahmad KA, Ahmed K, et al. Role of protein kinase CK2 in the regulation of tumor necrosis factor-related apoptosis inducing ligand-induced apoptosis in prostate cancercells[J]. Cancer Res, 2006, 15, 66(4): 2242-2249
[15]. Shankar S, Singh TR, Fandy TE, et al. Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways[J]. Int J Mol Med, 2005, 16(6): 1125-1138
[16]. Abdollahi T, Robertson NM, Abdollahi A , et al. Inhibition of TRAIL-induced apoptosis by IL-8 is mediated by the p38-MAPK pathway in OVCAR3 cells[J]. Apoptosis, 2005, 10(6): 1383-1393
[17]. Yibin Deng, Yahong Lin, and Xiang wei Wu. TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO[J]. Gene Development, 2002, 16:33-45
[18]. Griffith TS, Rauch CT, Smolak PJ, et al. Functional analysis of TRAIL receptors usingmonoclonal antibodies[J]. J Immunol, 1999, 1, 162(5): 2597-2605
[19]. Leverkus M, Neumann M, Mengling T, et al. Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes[J]. Cancer Res, 2000, 1, 60(3): 553-559
[20]. Zhang XD, Franco AV, Nguyen T, et al. Differential localization and regulation of death and decoy receptors for TNF-related apoptosis-inducing ligand (TRAIL) inhuman melanomacells[J]. J Immunol, 2000, 15, 164(8): 3961-3970
[21]. Kuang AA, Diehl GE, Zhang J, et al. FADD is required for DR4- and DR5-mediated apoptosis: lack of TRAIL-induced apoptosis in FADD-deficient mouse embryonic fibroblasts[J]. J BiolChem, 2000, 18, 275(33): 25065-2508
[22]. Song JH, Bellail A, Tse MC, et al. Human astrocytes are resistant to Fas ligand and tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis[J]. J Neurosci, 2006, 22, 26(12): 3299-3308
[23]. Zhang XD, Wu JJ, Gillespie S , etal. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin[J]. Clin Cancer Res, 2006, 15, 12(4): 1355-1364
[24].Han J, Goldstein LA, Gastman BR, et al. Interrelated Roles for Mcl-1 and BIM in Regulation of TRAIL-mediated Mitochondrial Apoptosis[J]. J Biol Chem, 2006, 14, 281(15): 10153-10163
[25] .MacFarlane M, Merrison W, et al. Bratton SB, Cohen GM. Proteasome-mediated degradation of Smac during apoptosis: XIAP promotes Smac ubiquitination in vitro[J]. J Biol Chem. 2002 Sep 27;277(39): 36611-3616.
[26] .Kontny HU, Hammerle K, Klein R, et al. Sensitivity of Ewing's sarcoma to TRAIL-induced apoptosis[J]. Cell Death Differ, 2001, 8(5): 506-514
[27] .MitsiadesN, Mitsiades CS, Poulaki V, et al. Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells[J]. Blood, 2002, 15, 99(6): 2162-2171
[28] .Mitsiades N, Poulaki V, Mitsiades C, etal. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5[J]. Cancer Res. , 2001, 15, 61(6): 2704-2712
[29].Petak I, Vernes R, Szucs KS, et al. A caspase-8-independent component in TRAIL/Apo-2L-induced cell death in human rhabdomyosarcoma cells[J]. Cell Death Differ. , 2003 , 10(6): 729-739
[30] .Petak I, Douglas L. Tillman DM, et al. Pediatric rhabdomyosarcoma cell lines are resistant to Fas-induced apoptosis and highly sensitive to TRAIL-induced apoptosis[J]. Clin Cancer Res. , 2000 , 6(10): 4119-4127
[31]. Saitou Y, Shiraki K, Yamanaka T, et al. Augmentation of tumor necrosis factor family-induced apoptosis by E3330 in human hepatocellular carcinoma cell lines via inhibition of NF kappa B[J]. World J Gastroenterol, 2005, 28, 11(40): 6258-6261
[32].Tafuku S, Matsuda T, Kawakami H et, et al. Potential mechanism of resistance to TRAIL-induced apoptosis in Burkitt's lymphoma[J]. Eur J Haematol, 2006, 76(1): 64-74
[33] .Tanaka H, FujitaN, TsuruoT, etal. 3-Phosphoinositide-dependent protein kinase-1-mediated IkappaB kinase beta (IkkB) phosphorylation activates NF-kappaB signaling[J]. J Biol Chem, 2005, 9, 280(49), 40965-40973
[34] .Kumari AL, Ali AM, Das S, et al. Role of STAT3 and NFkappaB signaling in the serum factor-induced apoptosis in AK-5 cells[J]. Biochem Biophys Res Commun. , 2005, 28, 336(3): 860-867
[35] .Lakshmikanthan V, Kaddour-Djebbar I, Lewis RW, et a.SAHA-sensitized prostate cancer cells to TNFalpha-related apoptosis-inducing ligand (TRAIL): Mechanisms leading to synergistic apoptosis[J]. Int J Cancer, 2006, 119(1): 221-228
[36].Yamaguchi Y, ShirakiK, Fuke H, etal. Targeting of X-linked inhibitor of apoptosis protein or survivin by short interfering RNAs sensitize hepatoma cells to TNF-related apoptosis-inducing ligand- and chemotherapeutic agent-induced cell death[J]. Oncol Rep, 2005, 14(5): 1311-1316
[37]. Inoue T, Shiraki K, Fuke H, et al. Proteasome inhibition sensitizes hepatocellular carcinoma cells to TRAIL by suppressing caspase inhibitors and AKT pathway[J]. Anticancer Drugs, 2006, 17(3): 261-268
[38].Enokimura N, Shiraki K, Kawakita T, et al. Vitamin K analog (compound 5) induces apoptosis in human hepatocellular carcinoma independent of the caspase pathway[J]. Anticancer Drugs, 2005 , 16(8): 837-844
[39].Han J, Goldstein LA, Gastman BR, etal. Rabinowich H. Interrelated Roles for Mcl-1 and BIM in Regulation of TRAIL-mediated Mitochondrial Apoptosis[J]. J Biol Chem, 2006 , 14;281(15): 10153-10163
[40].Ravi R, Fuchs EJ, Jain A, et al. Resistance of cancers to immunologic cytotoxicity and adoptive immunotherapy via X-linked inhibitor of apoptosis protein expression and coexisting defects in mitochondrial death signaling[J]. Cancer Res, 2006 , 66(3): 1730-1739
[41] .KM, Tan M, Sun Y, et al. A small molecule Smac-mimic compound induces apoptosis and sensitizes TRAIL- and etoposide-induced apoptosis in breast cancer cells[J]. Oncogene, 2005, 24(49): 7381-7388
[42].Hinz S, Trauzold A, Boenicke L, et al. Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis[J]. Oncogene, 2000, 16, 19(48): 5477-5486
[43] .Zhang XD, Zhang XY , Gray CP, et al. Tumor necrosis factor-re-lated apo ptos is-inducing ligand-induced apoptosis of human melanolYlais r-ulated by srnac /DiABLO release from m / tochondna[J]. Cancer Res, 2001, 61(19): 7339-7348
[44] .Munshi A, McDonnell TJ, Meyn RE, et al. Chemotherapeutic agents enhance TRAIL-induced apoptosis in prostate cancer cells. Cancer Chemother Pharmacol[J]. 2002, 50(1): 46-52
[45].KangJ, BuJ, Hao Y, et al. Subtoxic concentration of doxorubicin enhances TRAIL-induced apoptosis in human prostate cancer cell line LNCaP[J]. Prostate Cancer Prostatic Dis. , 2005, 8(3): 274-279
[46] .LeBlancH, LawrenceD, VarfolomeevE, et al. Turnor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homologBax[J]. Nat Med, 2002, 8(3): 274—281
[47] .Kandasamy K, Srinivasula SM , Alnemri ES, et al. Involvement of proapo ptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apo ptos is: differential regulation of cytochmmec and Smac / DIABLO release[J]. Cancer Res, 2003, 63(7): 1712-1721
[48] .Kim M, Jung SO, Park K, et al. Detection of Bax protein conformational change using a surface plasmon resonance imaging-based antibody chip[J]. Biochem Biophys Res Commun, 2005, 30, 338(4): 1834-1838
[49] .Baillat G, Garrouste F, Remacle-Bonnet M, et al. Bcl-xL/Bax ratio is altered by IFNgamma in TNFalpha- but not in TRAIL-induced apoptosis in colon cancer cell line[J]. Biochim Biophys Acta, 2005, 15, 1745(1): 101-110
[50].Wendt J, von Haefen C, Hemmati P, et al. TRAIL sensitizes for ionizing irradiation-induced apoptosis through an entirely Bax-dependent mitochondrial cell death pathway[J]. Oncogene, 2005, 9, 24(25): 4052-4064
[51].von Haefen C, Gillissen B, Hemmati PG, et al. Multidomain Bcl-2 homolog Bax but not Bak mediates synergistic induction ofapoptosis by TRAIL and 5-FU throμtgh the mitochondrial apoptosis pathway[J]. Oncogene, 2004, 28, 23(50): 8320-8332
[52]. Beresford SA, Davies MA, Gallick GE, et al. Donato NJ. Differential effects of phosphatidylinositol-3/Akt-kinase inhibition on apoptotic sensitization to cytokines in LNCaP and PCc-3 prostate cancer cells[J]. J Interferon Cytokine Res, 2001, 21(5): 313-322
[53]. Yoshida S, Narita T, Koshida S, et al. TRAIL/Apo2L ligands induce apoptosis in malignant rhabdoid tumor cell lines[J]. Pediatr Res, 2003, 54(5): 709-717
[54]. Dubska L, Andera L, Sheard MA, et al. HER2 signaling downregulation by trastuzumab and suppression of the PI3K/Akt pathway: an unexpected effect on TRAIL-inducedapoptosis[J]. FEBS Lett, 2005, 1, 579(19): 4149-4158
[55]. Tamai M, Kawakami A, Tanaka F, et al. Significant inhibition of TRAIL-mediated fibroblast-like synovial cell apoptosis by IFN-gamma throμgh JAK/STAT pathway by translational regulation[J]. J Lab Clin Med, 2006, 147(4): 182-190
[56]. Yamai M, Kawakami A, Tanaka F. Significant inhibition of TRAIL-mediated fibroblast-like synovial cell apoptosis by IFN-gamma throμgh JAK/STAT pathway by translational regulation[J]. J Lab Clin Med, 2006, 147(4): 182-190
[57]．李小安，房殿春，司佩任，等．TRAIL诱导肝癌细胞系SMMC—7721的凋亡作用[J]．世界华人消化杂志[J]。2003，11，9：1369-1371
[58]．何松青，陈彦，陈孝平．TRAIL的抗肝细胞癌作用研究[J]．中华肝胆外科杂志[J]．2003，9，11：670-673
[59]．杨柳芹，房殿春．α-生育酚对TRAIL诱导胃癌细胞凋亡的影响及机制[J]．解放军医学杂志[J]．2005，30，9：779-781
[60]. Ma H, Liu Y, Liu S, et al. Oral adeno-associated virus- TRAIL gene therapy suppresses human hepatocellular carcinoma growth in mice[J]. Hepatology, 2005, 42(6): 1355-1363
[61]. Kaliberov SA, Kaliberova LN, Stockard CR, et al. Buchsbaum DJ. Adenovirus-mediated FLT1 -targeted proapoptotic gene therapy of human prostate cancer[J]. Mol Ther, 2004, 10(6): 1059-1070
[62].Kazhdan I, Marciniak RA, et al. Death receptor 4 (DR4) efficiently kills breast cancer cells irrespective of their sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)[J]. Cancer Gene Ther, 2004, 11(10):691-698
[63 ]. Jacob D, Davis J, Schumacher G, et al. Adenoviral vector expressing the TRAIL gene driven by the hTERT promoter[J]. Z Gastroenterol, 2004, 42(12): 1363-1370
[64]. Reddy RM, Tsai WS, Ziauddin MF, et al. Cisplatin enhances apoptosis induced by a tumor-selective adenovirus expressing tumor necrosis factor-related apoptosis-inducing ligand[J]. J Thorac Cardiovasc Surg, 2004, 128(6): 883-891
[65] .Shankar S, Chen X, Srivastava RK. Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo[J]. Prostate, 2005, 1, 62(2): 165-186
[66].Nagane M, Pan G, WeddleJJ. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo[J]. cancer Res, 2000, 15, 60(4): 847-853
[67]. Singh TR , Shankar S, Chen X, et al. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor—related apoptosis-inducing ligand/ApoL-2 ligand on apoptosis and on regression of breast carcino-ma in vivo[J]. Cancer Res, 2003, 63(17): 5390-5400
[68]. Ahucci L, Rossin A, Raffelsberger W, et al. Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL Nat Med, 2001, 7(6): 680—686
[69] .Keane MM, Rubinstein Y, CuelloM. Inhibition of NF-kappaB activity enhances TRAIL mediated apoptosis in breast cancer cell lines. Breast Cancer Res Treat[J]. 2000 Nov;64(2): 211-219.
[70] .Chopin V, SlomiannyC, Hondermarck H. Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21(wafl)[J]. ExpCellRes, 2004, 15, 298(2): 560-573
[71]. Walczak H, Bouchon A, Stahl H. Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2-or Bcl-xL-overexpressing hemotherapy-resistant tumor cells[J]. Cancer Res, 2000, 1, 60(11): 3051-3057
[72]. Wang S, El-Deiry WS, et al. Inducible silencing of KILLER/DR5 in vivo promotes bioluminescent colon tumor xenograft growth and confers resistance to chemotherapeutic agent5-fluorouracil[J]. Cancer Res, 2004, 64(18): 6666-6672.
[73]. Ashkenazi, A., Pai, et al. Safety and antitumor activity of recombinant solubleApo2 ligand[J]. J. Clin. Invest, 1999, 104, 155-162
[74]. Jin TG, Kurakin A, Benhaga N. Fas-associated protein with death domain (FADD)-independent recruitment of c-FLIPL to death receptor 5[J]. J Biol Chem, 2004, 31, 279(53): 55594-55601
[75]. Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosisfactor-related apoptosis-inducing ligand in vivo[J]. Nat. Med. (1999)5, 157-163
[76]. Horinaka M, Yoshida T, Shiraishi T, et al. The combination of TRAIL and luteolin enhances apoptosis in human cervical cancer HeLa cells[J]. Biochem Biophys Res Commun, 2005, 333(3): 833-838
[77]. Shi RX, Ong CN. Shen HM. Protein kinase C inhibition and x-linked inhibitor of apoptosis protein degradation contribute to the sensitization effect of luteolin on tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in cancer cells[J]. Cancer Res, 2005, 65(17): 7815-7823
[78]．朱琳，李慧荣，吴建，等．宫颈癌细胞TRAIL死亡受体和诱骗受体表达的研究[J]．现代妇产科进展，2005，14，4：277-280
[79]. Kim CY, Jeong M, Mushiake H, et al. Cancer gene therapy using a novel secretable trimeric TRAIL[J]. Gene Ther, 2006, 13(4): 330-338
[80]. Hougardy BM, Maduro JH, van der Zee AG, et al. Proteasome inhibitor MG132 sensitizes HPV-positive human cervical cancer cells to rhTRAIL-induced apoptosis[J]. Int J Cancer, 2006, 15, 118(8): 1892-1900
[81] .Garnett TO, Filippova M. Duerksen-Hughes PJ, et al. Accelerated degradation of FADD and procaspase 8 in cells expressing human papilloma virus 16 E6 impairs TRAIL-mediated apoptosis[J]. Cell Death Differ, 2006, 10, [Epub ahead of print]
[82].Lee MW, Bach JH, Lee HJ, et al. The activation of ERK1/2 via a tyrosine kinase pathway attenuates TRAIL-induced apoptosis in HeLa cells[J]. Cancer Invest, 2005, 23(7): 586-592